[go: up one dir, main page]

CA2494069A1 - Capsule de gelatine resistant aux pellicules - Google Patents

Capsule de gelatine resistant aux pellicules Download PDF

Info

Publication number
CA2494069A1
CA2494069A1 CA002494069A CA2494069A CA2494069A1 CA 2494069 A1 CA2494069 A1 CA 2494069A1 CA 002494069 A CA002494069 A CA 002494069A CA 2494069 A CA2494069 A CA 2494069A CA 2494069 A1 CA2494069 A1 CA 2494069A1
Authority
CA
Canada
Prior art keywords
composition
gelatin
dosage form
drug
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494069A
Other languages
English (en)
Inventor
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494069A1 publication Critical patent/CA2494069A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention porte sur des compositions qui sont utilisées dans la préparation de capsules de gélatine, sur des capsules de gélatine présentant une réticulation réduite, et sur des procédés de préparation de ces capsules de gélatine.
CA002494069A 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules Abandoned CA2494069A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US39986202P 2002-07-31 2002-07-31
US39986302P 2002-07-31 2002-07-31
US39977602P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US60/399,862 2002-07-31
US60/399,776 2002-07-31
US60/399,863 2002-07-31
US60/399,808 2002-07-31
PCT/US2003/024042 WO2004010972A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules

Publications (1)

Publication Number Publication Date
CA2494069A1 true CA2494069A1 (fr) 2004-02-05

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
CA002493980A Abandoned CA2493980A1 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
CA002493974A Abandoned CA2493974A1 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite
CA002494069A Abandoned CA2494069A1 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules
CA002494358A Abandoned CA2494358A1 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002493980A Abandoned CA2493980A1 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
CA002493974A Abandoned CA2493974A1 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002494358A Abandoned CA2494358A1 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage

Country Status (7)

Country Link
EP (4) EP1526846A2 (fr)
JP (4) JP2005538102A (fr)
AU (4) AU2003257102A1 (fr)
BR (4) BR0313150A (fr)
CA (4) CA2493980A1 (fr)
MX (4) MXPA05000862A (fr)
WO (4) WO2004010972A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103582A2 (fr) 2002-06-05 2003-12-18 Ivax Corporation Reduction de la reticulation de gelatine
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
ATE485033T1 (de) * 2005-07-26 2010-11-15 Nicox Sa Pharmazeutische formulierung von nitrooxy- derivaten von nsar
JP5503939B2 (ja) * 2009-10-16 2014-05-28 東洋カプセル株式会社 アゼラスチン塩酸塩含有カプセル剤
JP6887456B2 (ja) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
KR20220077091A (ko) * 2020-12-01 2022-06-08 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제
CN113230241A (zh) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 三羟甲基氨基甲烷盐在治疗心脑血管病的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (fr) * 1972-11-01 1976-05-14
US4349529A (en) * 1980-04-14 1982-09-14 E. R. Squibb & Sons, Inc. Diagnostic and therapeutic capsules and method of producing
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
FR2617047B1 (fr) * 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
JP2790659B2 (ja) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 ゼラチンカプセル剤
KR100338851B1 (ko) * 1994-03-15 2002-10-12 센주 세이야꾸 가부시키가이샤 프라노프로펜의안정화방법및안정한프라노프로펜약제
IT1269583B (it) * 1994-04-26 1997-04-08 Bayer Italia Spa Preparazioni farmaceutiche a base di una soluzione di ketoprofene in capsule di gelatina molle e metodo per la loro produzione
DK0695544T3 (da) * 1994-08-05 2001-01-02 Shionogi & Co Hårde gelatinekapsler, der kan modstå denaturering, og fremgangsmåde til fremstilling heraf
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Also Published As

Publication number Publication date
AU2003257981A8 (en) 2004-02-16
JP2005538993A (ja) 2005-12-22
WO2004010972A3 (fr) 2004-07-29
WO2004022032A3 (fr) 2004-08-12
AU2003257102A8 (en) 2004-03-29
AU2003257982A8 (en) 2004-02-16
CA2494358A1 (fr) 2004-02-05
AU2003257102A1 (en) 2004-03-29
JP2006500389A (ja) 2006-01-05
AU2003257981A1 (en) 2004-02-16
JP2005538994A (ja) 2005-12-22
BR0313064A (pt) 2005-06-28
BR0313150A (pt) 2005-06-28
WO2004022032A2 (fr) 2004-03-18
MXPA05001166A (es) 2005-05-16
EP1526844A2 (fr) 2005-05-04
AU2003257103A8 (en) 2004-02-16
WO2004010972A2 (fr) 2004-02-05
EP1526846A2 (fr) 2005-05-04
EP1526845A2 (fr) 2005-05-04
WO2004010973A3 (fr) 2004-08-05
JP2005538102A (ja) 2005-12-15
MXPA05001272A (es) 2005-04-28
WO2004010973A2 (fr) 2004-02-05
BR0312875A (pt) 2005-06-28
WO2004010974A2 (fr) 2004-02-05
WO2004010974A3 (fr) 2004-08-05
CA2493980A1 (fr) 2004-02-05
BR0313149A (pt) 2005-06-28
EP1526847A2 (fr) 2005-05-04
MXPA05001167A (es) 2005-05-16
AU2003257103A1 (en) 2004-02-16
AU2003257982A1 (en) 2004-02-16
MXPA05000862A (es) 2005-04-19
CA2493974A1 (fr) 2004-03-18

Similar Documents

Publication Publication Date Title
US20040131670A1 (en) Pellicle-resistant gelatin capsule
EP1492527B1 (fr) Procede pour preparer une composition pharmaceutique finement auto-emulsifiable
US20030105141A1 (en) Finely self-emulsifiable pharmaceutical composition
US20030045563A1 (en) Pharmaceutical composition having reduced tendency for drug crystallization
US20040105885A1 (en) Gelatin capsule exhibiting reduced cross-linking
SA90100287B1 (ar) كبسولات صيدلية تحتوي على رانيتيدين
CA2494069A1 (fr) Capsule de gelatine resistant aux pellicules
JPS6024767B2 (ja) 腸溶性硬カプセル剤
US20040105884A1 (en) Pharmaceutical dosage form comprising a sulfite compound
US20040105883A1 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
AU2019225236B2 (en) Pharmaceutical dosage form for an emulsion of simethicone and loperamide
JP2008543851A (ja) 催吐剤封入カプセル
ZA200307575B (en) Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2inhibitor), a solvent, a fatty acid and an organic amine.
CA2098410A1 (fr) Capsules pharmaceutiques molles renfermant de la clonixinate de lysine; methode de preparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead